Document Detail


Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody.
MedLine Citation:
PMID:  16722329     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Allergic diseases of the airways, including asthma and allergic rhinitis, remain highly prevalent with associated symptoms placing considerable restrictions on the physical, emotional, and social functioning of the affected individual. It is now recognized that immunoglobulin E (IgE) plays a central role in mediating the allergic response that follows exposure to allergens after an initial process of sensitization. This sensitization process results in the overproduction of antigen-specific IgE. Omalizumab, a recombinant humanized monoclonal antibody, is the first therapeutic agent specifically targeting IgE. It has been investigated extensively in the treatment of patients with allergic diseases and is approved in the United States only for the treatment of patients with moderate-to-severe persistent asthma. Although not currently approved by the Food and Drug Administration for this specific indication, omalizumab also has been shown to be effective in patients with seasonal and perennial allergic rhinitis. As expected with a systemic anti-IgE agent, omalizumab also has been found to be helpful in the treatment of patients with concomitant asthma and allergic rhinitis. The efficacy of omalizumab in a range of allergic diseases reaffirms the importance of IgE in the pathogenesis of these conditions and shows the potential benefit to be obtained by inhibiting IgE, especially in patients with more severe and comorbid allergic diseases.
Authors:
William E Berger
Related Documents :
16426249 - Association between neopterin in cord blood, urinary neopterin in early childhood and t...
18940139 - Strategies for primary prevention of atopy in children.
19160939 - Exploring the distal lung: new direction in asthma.
6739379 - What is atopy? sidestepping semantics.
18431989 - Diagnostic criteria for house dust mites sensitized allergic patients.
21990499 - Bilateral inferior petrosal sinus sampling.
970229 - A validation of cause-of-death certification in 1,156 deaths.
23140039 - The validity of peak nasal inspiratory flow as a screening tool for nasal obstruction.
17554699 - Association of serotypes of streptococcus pneumoniae with disease severity and outcome ...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Allergy and asthma proceedings : the official journal of regional and state allergy societies     Volume:  27     ISSN:  1088-5412     ISO Abbreviation:  Allergy Asthma Proc     Publication Date:    2006 Mar-Apr
Date Detail:
Created Date:  2006-05-25     Completed Date:  2006-07-17     Revised Date:  2013-01-18    
Medline Journal Info:
Nlm Unique ID:  9603640     Medline TA:  Allergy Asthma Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S29-32     Citation Subset:  IM    
Affiliation:
Mission Viejo Medical Center, Mission Viejo, California 92691, USA. weberger@uci.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Anti-Idiotypic / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Hypersensitivity, Immediate / diagnosis,  drug therapy*
Male
Prognosis
Rhinitis, Allergic, Perennial / diagnosis,  drug therapy*
Risk Assessment
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Anti-Idiotypic; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/anti-IgE antibodies; 0/omalizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of asthma with anti-immunoglobulin E monoclonal antibody.
Next Document:  Anti-immunoglobulin E monoclonal antibody administered with immunotherapy.